Latest news

Issue of Options

20 December 2017

Patent Grants in Japan & China for TYK2 Inhibitors

19 December 2017

Results of AGM

14 December 2017

AGM Statement

14 December 2017

Find out more


Sareum actively seeks collaboration partners for its research programmes.

Find out more large-arrow.png


Sareum has an innovative pipeline of drug development candidates.

Find out more large-arrow.png


Biotech Capital, Feb 2017 (Video)

  • @Sareumplc Latest tweet

    Eli Lilly's Chk1 inhibitor, prexasertib, shows clinical activity in ovarian cancer. Update from Sierra Oncology on… via @Sareumplc
    View more